Month: September 2021

MINNEAPOLIS, Sept. 17, 2021 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced it will be added as a member of the Russell 2000® and 3000® Indexes, effective after the U.S. market opens on September 20, as part of the Russell’s quarterly additions of select initial public offering (“IPO”) companies. “We are honored to be added to the Russell 2000® and 3000® Indexes just a few short months after our IPO, which reflects all of the progress we have made during 2021 to accelerate the commercial adoption of Barostim™, particularly in the U.S.,” said Nadim Yared, President and Chief Executive Officer of CVRx. “We look...

VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) — Major Precious Metals Corp. (“Major Precious Metals” or the “Company”) (CSE:SIZE | OTC:SIZYF | FRANKFURT:3EZ) is pleased to announce that it has successfully completed its Phase 1 diamond drilling program at its Skaergaard Project (“Skaergaard”) in Greenland with all planned drill hole depths covering an area of approximately 10 km² within the 7.5 km (east-west) by 11 km (north-south) Skaergaard intrusion, including key new target zones in the northern part of the Project. HighlightsA total of 32 diamond drill holes (8,195 m) were completed in several key target areas in the northern part of Skaergaard. These target areas were discussed in the Company’s August 26, 2021 news release. Approximately 240 m of channel samples were also collected from four separate areas...

MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021. In particular, the results of the interim analysis showed monalizumab in combination with durvalumab improved progression-free survival (PFS) and objective response rate (ORR) compared to durvalumab alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT). Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor...

Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021. In particular, the results of the interim analysis showed monalizumab in combination with durvalumab improved progression-free survival (PFS) and objective response rate (ORR) compared to durvalumab alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT). Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor...

Ambitious value creation plan targeting C$700 million of additional operating income, as well as a 57% operating ratio for 2022 Leveraging previous strategic investments and the strong condition of the existing network will bring capital spending down to approximately 17% of revenue for 2022 while retaining commitment to safety and customer service CN to resume share repurchase program previously authorized by Board of Directors with remaining C$1.1 billion in share repurchases to be completed by end of January 2022 MONTREAL, Sept. 17, 2021 (GLOBE NEWSWIRE) — CN (TSX: CNR, NYSE: CNI) today announced the details of its strategic and financial value creation plan, “Full Speed Ahead – Redefining Railroading,” which will allow CN to continue delivering high-quality service to customers while generating profitable growth and enhanced...

PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissuesAt 24 weeks, 38% of patients achieved ≥20% reduction in the volume of the PROS lesions assessed in the primary endpoint analysis; no patients experienced disease progression or death  Alpelisib is the first potential treatment to specifically address the root cause of PROS conditionsEPIK-P1 study findings presented at ESMO Virtual Congress 2021 support FDA submissionBasel, September 17, 2021— Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (PROS) who received treatment daily for at least 24 weeks. Results from EPIK-P1 showed...

– Clinical activity observed in all three mesothelin-expressing tumor types treated – Gavo-cel disease control rate (DCR) 81% with tumor regression in 15 of 16 evaluable patients – Overall response rate (ORR) 31% in patients infused with gavo-cel following lymphodepletion – Meaningful survival benefit at 11.2 months for patients with refractory mesothelioma – Recommended Phase 2 Dose (RP2D) being refined after identification of the Maximum Tolerated Dose (MTD) – TCR2 to host a conference call on Friday, September 17 at 9:00a.m. ET CAMBRIDGE, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced positive interim results from the ongoing Phase...

NFI is Leading the ZEvolutionNFI is Leading the ZEvolution to zero-emission and electric mobilityST. CLOUD, Min., Sept. 17, 2021 (GLOBE NEWSWIRE) — (TSX: NFI) NFI Group Inc. (“NFI” or the “Company”), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, today announced that the Central Ohio Transit Authority (“COTA”) has exercised options for 18 Xcelsior® compressed natural gas (“CNG”) forty-foot, heavy-duty transit buses, converted from NFI subsidiary New Flyer of America Inc.’s (“New Flyer”) backlog. The award follows COTA’s second option conversion of 28 CNG buses, delivered earlier this year. The options were exercised from a five-year contract originally announced in 2018 for 154 Xcelsior CNG forty-foot transit buses. Both purchases were supported by Federal Transit...

Pacifica, California location will become Captor’s Tenth Location TORONTO, Sept. 17, 2021 (GLOBE NEWSWIRE) — Captor Capital Corp. (CSE: CPTR; FRANKFURT: NMVA; STUTTGART: NMVA), (“Captor” or the “Company”), is pleased to announce that it has entered into a binding agreement to purchase a majority interest in a licensed dispensary location in Pacifica, California. The Pacifica dispensary location, which is approved for adult-use and medicinal cannabis use as well as delivery, is slated to become the tenth dispensary in Captor Capital’s California network, joining locations in Antioch, Atwater, El Sobrante, Salinas, Castroville, Santa Cruz, Lompoc, Goleta and Palm Springs. This location will be operated by Captor Retail Group (“CRG”) and the dispensary will become part of the One Plant brand. “We are excited...